Study in Kazakhstan reveals resistance of H. pylori to antibiotics amoxicillin and metronidazole
Read more
UzDaily
uzdaily.uz

Study in Kazakhstan reveals resistance of H. pylori to antibiotics amoxicillin and metronidazole

Researchers from Kazakhstan studied the bacterium Helicobacter pylori and found that it exhibits resistance to the drugs amoxicillin and metronidazole. The level of this resistance was 20.98% for amoxicillin and 20.58% for metronidazole, which calls into question the effectiveness of commonly used treatment methods.

The study results were presented on November 20 at an international conference on combating antimicrobial resistance held in Astana. The work emphasizes the need to consider local patterns of antibiotic resistance when treating this infection in Central Asian countries.

The study, titled 'Local Antibiotic Resistance of H. pylori as a Basis for Rational Antimicrobial Therapy in Kazakhstan,' was presented by specialists from the research laboratory of Peter Pospelov Karaganda Medical University. This work was conducted under grant IRN AP19575049 for the period from 2023 to 2025.

The main goal of the scientific project was to assess the sensitivity of H. pylori to antibiotics, identify genetic mechanisms of resistance, and study factors affecting treatment outcomes. Speaking at the conference, one of the researchers noted that Helicobacter pylori poses a problem not only because it causes chronic gastritis and peptic ulcers. Long-term infection with this bacterium is also an established risk factor for stomach cancer.

The International Agency for Research on Cancer (IARC) classifies H. pylori infection as a Group 1 carcinogen. However, the presence of the bacterium in a person does not guarantee the development of cancer.

Antibiotics Showing Resistance

During the study, 110 isolates of H. pylori were analyzed. The E-test method was used to assess the susceptibility of the bacteria to antimicrobial agents. According to the data obtained, resistance to amoxicillin reached 20.98%, while resistance to metronidazole was 20.58%.

Resistance levels for clarithromycin, tetracycline, and rifampicin were 9.8% each. The level of resistance to levofloxacin was lower—4.9%. The study authors considered the resistance to amoxicillin and metronidazole critical, as both indicators exceeded the 20% mark.

The authors called for a review of empirical treatment approaches where antibiotics are prescribed without prior testing of the specific pathogen's sensitivity. They proposed adapting clinical protocols to local data and considering alternative treatment regimens.

Levofloxacin showed the lowest percentage of resistance among the tested drugs, at 4.9%. Researchers suggested that this finding could be taken into account when selecting second-line treatment regimens. However, the authors warned that the results of one study do not automatically imply the prescription of the drug to all patients; treatment decisions must take into account current clinical guidelines, contraindications, and individual patient characteristics.

Genetic Studies Confirm Link Between Mutations and Resistance

In addition to checking antibiotic sensitivity, scientists conducted molecular genetic analysis using polymerase chain reaction (PCR). Mutations in genes associated with resistance to certain drugs, including PBP1, 23S rRNA, rdxA, and 16S rRNA, were studied. The study revealed a statistically significant correlation between certain genetic changes and phenotypic resistance in H. pylori.

Significant results were recorded regarding mutations associated with resistance to amoxicillin, clarithromycin, and metronidazole. The authors noted that molecular tests can facilitate the faster identification of resistant strains and assist doctors in choosing more appropriate therapy regimens.

Risk of Treatment Failure Was 2.43 Times Higher

The researchers also analyzed genetic factors that may affect the effectiveness of eradication therapy aimed at eliminating Helicobacter pylori. According to the results, the presence of the IceA2 genotype was associated with an increased risk of treatment failure. Patients with this genotype had approximately 2.43 times higher chances of unsuccessful cure (odds ratio: 2.429; p = 0.005).

The scientists believe that this genetic marker can be an additional factor in treatment planning.

Prescription Analysis Reveals Problems in Treatment Regimens

The study also included a retrospective analysis of 48 medical records of patients from a clinic in Karaganda in 2023. According to the analysis, dual antibiotic therapy was recorded in 22.9% of cases, metronidazole monotherapy in 25.7%, treatment only with proton pump inhibitors without antibiotics in 39.6%, and bismuth monotherapy in 21.6%.

The presenter clarified that the categories of prescriptions overlapped, leading to the total share exceeding 100%. The researchers concluded that the identified practices indicate a need for stricter control over prescriptions and better adherence to clinical guidelines.

Proposed measures include revising empirical treatment approaches based on local resistance patterns, implementing molecular diagnostics, and improving clinical practice audits.

Significance of Results for Uzbekistan

The work of Kazakhstani scientists highlights the importance of using data on local antibiotic resistance when choosing treatment methods for infections. The sensitivity of Helicobacter pylori to antimicrobial drugs can vary between different regions and countries. Consequently, treatment regimens that do not take into account local epidemiological conditions may be less effective.

For Uzbekistan, these findings are relevant in the context of developing laboratory diagnostics, studying local resistance patterns, and efforts toward rational antibiotic use. However, it is noted that the resistance rates recorded in Kazakhstan cannot be automatically applied to the population of Uzbekistan; local studies are necessary to assess the prevalence of resistant strains.

The study demonstrates how combining laboratory testing of antibiotic sensitivity, molecular genetic methods, and clinical practice analysis can contribute to improving treatment effectiveness.

Similar stories

Climate change may accelerate the spread of antibiotic resistance in Central Asia
Read more
uzdaily.uz

Climate change may accelerate the spread of antibiotic resistance in Central Asia

Climate change potentially could contribute to the spread of antibiotic resistance in the Central Asian region. Rising temperatures, floods, and water scarcity can affect the movement of resistant microorganisms, as well as the dissemination of antibiotic resistance genes in the environment.

These risks were voiced by Oksana Kravtsova, a representative of the Central Asia Regional Environmental Centre (CAREC), during an international conference held in Astana on November 19. According to the information presented, climate changes can impact both the survival and spread of microorganisms and the transmission of resistance genes between bacteria.

One of the mechanisms under consideration is horizontal gene transfer—the process of exchanging genetic material associated with antimicrobial resistance between bacteria. The presentation refers to the results of a laboratory study published in the Journal of Hazardous Materials in 2024. In the experiment, increasing the water temperature from 5°C to 30°C led to an approximately 30-fold increase in the frequency of antibiotic resistance gene transfer.

However, the authors emphasize that these data pertain to a specific experimental system and do not imply a comparable increase in antimicrobial resistance, morbidity, or mortality in natural ecosystems of Central Asia.

In addition to rising temperatures, extreme weather events can play a significant role. Floods and heavy rains can carry pollutants from agricultural areas and livestock farms into surface waters, potentially increasing human and animal contact with resistant microorganisms. In turn, droughts and water shortages can alter water reuse practices, increasing the need for effective sanitation and water purification.

Dust storms are also a potential factor, as they can transport microbial material, but their contribution to the spread of antibiotic resistance genes in Central Asia requires further study.

For Uzbekistan, these issues are particularly relevant due to rising temperatures, water scarcity, irrigated agriculture, and intensive livestock farming. It is noted, however, that climate change is not the sole or necessarily primary cause of antibiotic resistance; the main factors remain the use of antibiotics in human and veterinary medicine, sanitary conditions, access to treatment, and the effectiveness of epidemiological surveillance systems.

Within the 'One Health' approach, experts advocate for considering human, animal, and environmental health as interconnected elements of a single system. This approach involves integrating clinical, veterinary, ecological, and climatic data to improve risk assessment and develop preventive measures. For Central Asia, one of the priority areas for future research may be studying seasonal links between temperature, extreme weather events, and the spread of resistant microorganisms. Such studies will help determine which specific climatic factors influence antibiotic resistance in regional conditions and what adaptive measures can mitigate potential risks.

The Importance of Rational Antibiotic Use and the Threat of Antimicrobial Resistance
Read more
cgtn.com

The Importance of Rational Antibiotic Use and the Threat of Antimicrobial Resistance

Unpleasant symptoms such as sore throat, runny nose, or earache can disrupt the normal daily routine. When symptoms become uncomfortable, some people take leftover antibiotics from previous illnesses, believing that recovery will happen faster.

However, antibiotics do not work against all infections. For example, if a sore throat is caused by a virus, an antibiotic will not eliminate the cause. Improper or unnecessary use can have serious consequences that extend far beyond a single episode of illness.

This everyday decision is linked to a much larger threat—antimicrobial resistance (AMR). As microorganisms become resistant to drugs designed to treat them, infections become harder to treat. Antibiotic resistance is a key part of this problem, jeopardizing the medications upon which modern healthcare depends.

Therefore, World Antimicrobial Awareness Week, held from November 18 to 24, is important for everyone. This year's theme, 'One Health, One Action: Preventing AMR Now,' calls for coordinated action in human, animal, and environmental health.

UN Children's Day on November 20, which falls within this week, serves as a reminder that protecting children's health also involves the rational use of antibiotics so that effective medicines remain available for future generations.

A Threat That Concerns Everyone

A study published in The Lancet in 2024 showed that bacterial AMR was directly responsible for 1.14 million deaths worldwide in 2021. According to the basic assessment of this study, bacterial AMR could potentially cause a cumulative 39.1 million deaths between 2025 and 2050.

These figures serve as a warning, not an inevitable future. AMR threatens not only the treatment of infections. Antibiotics contribute to improving the safety of procedures such as major surgery, organ transplantation, cancer treatment, and intensive care. If effective antibiotics become harder to use, many areas of modern medicine could face increased risks.

Not Every Sore Throat Requires Antibiotics

In otolaryngology practice, one of the most frequent discussions is explaining why an antibiotic may not be necessary. Most acute sore throats are caused by viruses, against which antibiotics are ineffective. Some cases are caused by bacteria, such as Group A Streptococcus, and may require treatment. A doctor's assessment and, if necessary, testing help determine the likely cause.

Sinusitis is another common source of misunderstanding. Yellow or green discharge in the nose does not automatically mean a bacterial infection; the color of the mucus itself cannot establish the cause. The updated adult sinusitis guideline from the American Academy of Otolaryngology–Head and Neck Surgery in 2025 advises clinicians to consider bacterial sinusitis if symptoms persist without improvement for at least 10 days or worsen after initial improvement. In uncomplicated cases, observation with guaranteed follow-up may be appropriate.

Earache also does not always require oral antibiotics. Treatment depends on the underlying condition, not just the symptom. When a patient asks for antibiotics, a simple statement of 'You don't need them' is rarely sufficient. Doctors must explain what the examination shows, why an antibiotic is unlikely to help, and what might relieve the symptoms. Patients must also know when they should return if their condition worsens or does not improve.

Not prescribing an unnecessary antibiotic is not the same as inaction. It is a clinical decision based on probable benefit and risk. Similarly, when a bacterial infection requires antibiotics, treatment should not be delayed due to concerns about resistance. The goal is not to avoid antibiotics at all costs, but to use them when they are likely to benefit the patient.

Patients and Doctors Share Responsibility

Some patients take antibiotics without medical advice, reuse leftover medication, or share prescriptions. Doctors may also feel pressure due to limited consultation time, diagnostic uncertainty, or patient expectations and prescribe drugs 'just in case.' Instead, prescriptions should be guided by clinical data, appropriate testing, and local resistance patterns.

Hospitals can support responsible use through antimicrobial stewardship, professional education, surveillance, and effective infection prevention. Patients should seek professional help rather than self-medicate and follow their doctor's instructions when antibiotics are prescribed.

Good communication is crucial. When patients understand why an antibiotic is not needed, they are more likely to accept an alternative treatment plan. Doctors must listen to their concerns, explain decisions in simple terms, and provide clear recommendations for further action. Responsible prescribing should build trust between doctors and patients, not create conflict.

Why Global Cooperation Matters

AMR crosses national borders and links human, animal, and environmental health. Resistant microorganisms and resistance genes can spread through direct contact, food, water, and improperly managed waste.

The 'One Health' approach recognizes these connections. Reducing the unnecessary use of antimicrobials in human healthcare, veterinary medicine, and agriculture must go hand-in-hand with vaccination, sanitation, food safety, infection prevention, and responsible waste management.

No single country can tackle AMR alone. Governments and researchers must share surveillance data and scientific knowledge, develop faster diagnostic tests, new drugs and vaccines, and help ensure access to effective diagnosis and treatment in resource-limited regions. In May 2026, the World Health Assembly adopted an updated Global Action Plan on Antimicrobial Resistance for the period 2026–2036, emphasizing the need for coordinated action across various sectors.

Protecting Future Medicines Starts Today

Individuals can help by not taking antibiotics for a common cold without consulting a doctor. Doctors can prescribe cautiously and explain their decisions. Hospitals and governments can invest in prevention, surveillance, research, and collaboration.

Protecting antibiotics does not mean refusing treatment for patients who need it. It means using these medicines wisely today so they can continue to save lives tomorrow.

Next time you have a sore throat or a runny nose, the most helpful question may not be 'Which antibiotic should I take?', but rather 'What is causing my symptoms and what treatment will actually work?'

WHO calls for strengthening the fight against antibiotic bacterial resistance
Read more
noticiasaominuto.com

WHO calls for strengthening the fight against antibiotic bacterial resistance

The World Health Organization (WHO) acknowledged advances in combating antimicrobial resistance, but emphasized the urgent need to intensify efforts in areas such as prevention, diagnosis, and correct antibiotic use.

Jean-Pierre Niemazi, interim director of the WHO's antimicrobial resistance department, warned at a press conference in Geneva that antimicrobial resistance is widespread and poses a serious threat to the future of modern medicine.

The emergence of resistance occurs because bacteria have developed the ability to resist drugs created to fight them, rendering many of these substances ineffective. This process has been aggravated by the massive use of antibiotics in humans, animals, and food production, driving the development of Antimicrobial Resistance (AMR) and making it one of the leading causes of infection-related mortality globally.

Niemazi stressed that drug-resistant infections cause deaths for years without full awareness of this dimension. According to the WHO, resistant superbugs are directly responsible for over one million deaths and contribute to about five million annual fatalities.

A survey conducted by the WHO in 183 countries showed that nearly ten out of ten nations have a national action plan against this problem, a significant increase compared to the 79 countries registered in 2017. However, Pravasha Prakash, technical officer of the WHO's AMR department, reported that only 42 nations declare having a plan that is simultaneously funded, implemented, and monitored.

Prakash warned that although countries are progressing in various phases, efforts need acceleration to meet the goals set for 2030, including a 10% reduction in deaths caused by antimicrobial resistance worldwide.

One of the main weaknesses identified is access to adequate diagnostics. Sylvia Bertagnolo, head of the surveillance unit for resistance and laboratory strengthening, reported that only 36% of countries have a national reference laboratory capable of testing the resistance of all fungi and bacteria monitored by the WHO, while the goal for 2030 is 80%.

Bertagnolo explained that without laboratory tests, healthcare professionals are forced to treat patients without knowing the origin of the infection or which antibiotic will be effective.

Recent data from the organization's global surveillance system indicate that in 2023, one in every six confirmed bacterial infections in the laboratory—among those reported to the WHO—showed resistance to the antibiotics used in treatment.

In response to this situation, the WHO announced the creation of two new tools to help countries strengthen their diagnostic capabilities. One specifies the tests that must be available at each level of the health system, from primary care to specialized hospitals. The other compiles 73 laboratory procedures, covering everything from sample collection to the identification of pathogenic agents and the performance of antibiotic sensitivity tests.

Despite the advances in diagnostics, the organization maintains that this is not enough. The WHO also advocates for improving the use of existing antibiotics, given that the emergence of new treatments does not keep pace with the progression of resistances.

Additionally, the WHO reiterates that infection prevention, vaccination, improved access to water and sanitation, along with appropriate antimicrobial use, are the central methods for combating antimicrobial resistance. Niemazi concluded the warning by stating that, without a stronger reaction, 39 million deaths could be attributed to antimicrobial resistance by 2050.

Popular